A new entrant in the race to shepherd antibodies for Alzheimer’s disease across the blood-brain barrier has emerged.
Korsana Biosciences emerged from stealth with $175 million to advance antibodies across the blood-brain barrier for Alzheimer’s disease, targeting a 2027 clinical debut.
Why it mattersKorsana's $175 million raise for blood-brain-barrier antibody delivery requires reprioritizing Alzheimer’s pipeline partnerships now.